ARMP Stock Risk & Deep Value Analysis
Armata Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ARMP Stock
We analyzed Armata Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARMP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is ARMP Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for ARMP?
- ⚠
Negative or inconclusive results from ongoing clinical trials (Anytime)
- ⚠
Delay in initiating Phase 3 trial or securing necessary funding (Q2 2026+)
- ⚠
Failure to secure strategic partnerships, leading to significant dilution (Q3 2026+)
- ⚠
Regulatory setbacks or new competitors entering the phage therapy space (Ongoing)
Unlock ARMP Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Armata Pharmaceuticals Inc (ARMP) Do?
Market Cap
$231.91M
Sector
Healthcare
Industry
Biotechnology
Employees
60
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Visit Armata Pharmaceuticals Inc WebsiteIs ARMP Stock Undervalued?
Unlock the full AI analysis for ARMP
Get the complete DVR score, risk analysis, and more
Does ARMP Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Armata's moat is currently being built through its proprietary phage cocktails, intellectual property protecting their composition and methods of use, and first-mover advantage in navigating the regulatory pathway for phage therapy. Successful clinical trials and subsequent approvals would solidify its leadership and create significant barriers to entry for competitors. The specialized nature of phage manufacturing and the complexity of developing effective cocktails also contribute to durability.
Moat Erosion Risks
- •Failure of clinical trials to demonstrate efficacy or safety
- •Emergence of superior or more cost-effective alternative treatments for AMR
- •Patent challenges or expiration of key IP
ARMP Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ARMP Stock Higher?
Near-Term (0-6 months)
- •Updated clinical timeline or details on Phase 3 design for AP-SA02 (Q2 2026)
- •Potential strategic partnership discussions or non-dilutive funding announcements (Q3-Q4 2026)
Medium-Term (6-18 months)
- •Initiation of pivotal Phase 3 trial for AP-SA02 (Late 2026 - Early 2027)
- •Additional data readouts from earlier-stage programs or new indications (2027)
- •Potential grant funding or government collaborations in AMR space (2027)
Long-Term (18+ months)
- •Successful completion and readout of Phase 3 trial, leading to regulatory submission (2028-2029)
- •Commercialization of first phage therapy product for antibiotic-resistant infections (2029+)
- •Expansion of phage library and platform into multiple therapeutic areas beyond critical infections
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ARMP?
- ✓
Positive updates on Phase 3 trial initiation and enrollment rates
- ✓
Announcements of non-dilutive funding or major pharmaceutical partnerships
- ✓
Improvement in cash runway and burn rate management
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARMP (Armata Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
